TY - JOUR
T1 - Mitochondrial medicine for aging and neurodegenerative diseases
AU - Reddy, P. Hemachandra
N1 - Funding Information:
Acknowledgments I sincerely thank Drs. Maria Manczak and Wei Zhao (postdoctoral scientists in the lab) for their technical assistance of MitoQ and SS-31 treatments of N2a cells. The research presented in this article was supported by grants from the American Federation for Aging Research, National Institutes of Health (AG028072 and AG026051), and KaloBios Pharmaceuticals, Inc.
PY - 2008/12
Y1 - 2008/12
N2 - Mitochondria are key cytoplasmic organelles, responsible for generating cellular energy, regulating intracellular calcium levels, altering the reduction-oxidation potential of cells, and regulating cell death. Increasing evidence suggests that mitochondria play a central role in aging and in neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Freidriech ataxia. Further, several lines of evidence suggest that mitochondrial dysfunction is an early event in most late-onset neurodegenerative diseases. Biochemical and animal model studies of inherited neurodegenerative diseases have revealed that mutant proteins of these diseases are associated with mitochondria. Mutant proteins are reported to block the transport of nuclear-encoded mitochondrial proteins to mitochondria, interact with mitochondrial proteins and disrupt the electron transport chain, induce free radicals, cause mitochondrial dysfunction, and, ultimately, damage neurons. This article discusses critical issues of mitochondria causing dysfunction in aging and neurodegenerative diseases, and discusses the potential of developing mitochondrial medicine, particularly mitochondrially targeted antioxidants, to treat aging and neurodegenerative diseases.
AB - Mitochondria are key cytoplasmic organelles, responsible for generating cellular energy, regulating intracellular calcium levels, altering the reduction-oxidation potential of cells, and regulating cell death. Increasing evidence suggests that mitochondria play a central role in aging and in neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Freidriech ataxia. Further, several lines of evidence suggest that mitochondrial dysfunction is an early event in most late-onset neurodegenerative diseases. Biochemical and animal model studies of inherited neurodegenerative diseases have revealed that mutant proteins of these diseases are associated with mitochondria. Mutant proteins are reported to block the transport of nuclear-encoded mitochondrial proteins to mitochondria, interact with mitochondrial proteins and disrupt the electron transport chain, induce free radicals, cause mitochondrial dysfunction, and, ultimately, damage neurons. This article discusses critical issues of mitochondria causing dysfunction in aging and neurodegenerative diseases, and discusses the potential of developing mitochondrial medicine, particularly mitochondrially targeted antioxidants, to treat aging and neurodegenerative diseases.
KW - Adenosine triphosphate
KW - Alzheimer's disease
KW - Amyloid beta
KW - Amyloid precursor protein
KW - Amyotrophic lateral sclerosis
KW - Caloric restricted
KW - Electron transport chain
KW - FRDA
KW - Freidriech ataxia
KW - Huntington's disease
KW - Hydrogen peroxide
KW - Mitochondrial DNA
UR - http://www.scopus.com/inward/record.url?scp=60349108806&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60349108806&partnerID=8YFLogxK
U2 - 10.1007/s12017-008-8044-z
DO - 10.1007/s12017-008-8044-z
M3 - Review article
C2 - 18566920
AN - SCOPUS:60349108806
SN - 1535-1084
VL - 10
SP - 291
EP - 315
JO - NeuroMolecular Medicine
JF - NeuroMolecular Medicine
IS - 4
ER -